<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690065</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107AKR07T</org_study_id>
    <nct_id>NCT01690065</nct_id>
  </id_info>
  <brief_title>Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML</brief_title>
  <acronym>NICE-BORA</acronym>
  <official_title>Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Korean Society of Hematology CML working party</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ulsan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard therapy in previously untreated adults with chronic phase (CP) of CML is
      imatinib and the result of long-term follow-up of IRIS study proves that imatinib for CML CP
      is reasonable therapy.(1, 2) However, some patients were initially diagnosed as advanced CML,
      accelerated phase (AP) or blastic phase (BP). Various chemotherapies were tried and were
      found that there were no highly effective chemotherapies for CML BP.(3-11) Imatinib in
      patients with these advanced CML is also disappointing because of low response rates as well
      as short response duration, and sudden transformation to BC is found even in initial CML CP
      patients. (12-17). Recent studies showed that nilotinib or dasatinib is better than imatinib
      in terms of rapid response and higher molecular response in newly diagnosed CML
      patients.(18-21) More potent bcr-abl suppression of nilotinib is supposed to be more active
      than imatinib even in patients with advanced CML. However, nilotinib in patients with
      imatinib-resistant or -intolerant CML BP showed low hematologic response and major
      cytogenetic response.(22, 23)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. IMATINIB COMBINED WITH CHEMOTHERAPY FOR PHYLADELPHIA POSITIVE ACUTE LYMPHOBLASTIC
           LYMPHOMA (PH+ ALL) The trials combining imatinib with high-dose chemotherapy were
           successfully resulting in high response rate and longer survival and a role for bridging
           therapy to allogeneic hematopoietic stem cell transplantation (alloHSCT) by means of
           concurrent or alternating regimen in patients with Philadelphia-positive (Ph+) acute
           lymphoblastic leukemia (ALL).(24-29) Current combination therapy of imatinib and
           chemotherapy became standard therapy of Ph+ ALL and new 2nd generation TKIs are
           investigating. These experiences may be translated into the treatment of CML BP.

        2. HIGH-DOSE DAUNORUBICIN IN ACUTE MYELOID LEUKEMIA (AML) INDUCTION CHEMOTHERAPY Two
           recently published papers of randomized trials comparing standard dose daunorubicin (45
           mg/m2 for 3 days) and high dose daunorubicin (90 mg/m2 for 3 days) demonstrated improved
           CR rate and survival with high dose daunorubicin in younger (60 years or younger) and
           older (over 60 years) patients, respectively.(30, 31) Therefore high-dose daunorubicin
           can be applied safely and effectively to the treatment of CML BP.

        3. NILOTINIB COMBINED WITH CHEMOTHERAPY FOR PHYLADELPHIA POSITIVE CML MYELOID BLASTIC PHASE
           (MBP) OR PHYLADELPHIA POSITIVE AML We will try 2nd generation TKI, nilotinib and
           high-dose daunorubicin induction chemotherapy combination to find out the combination
           therapy can improve response rate and survival in patients with CML MBP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Within 8 weeks after induction therapy</time_frame>
    <description>Primary purpose of this study is to define the efficacy of combined chemotherapy and nilotinib in chronic myeloid leukemia (CML) myeloid blastic phase (MBP) and bcr-abl positive acute myeloid leukemia (AML). The efficacy will be evaluated by complete remission (CR) rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Within 8 weeks after induction therapy</time_frame>
    <description>This study will also evaluate the safety of nilotinib and chemotherapy combination therapy.
CTCAE ver. 4.03 will be used for safety measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-dependent variables</measure>
    <time_frame>at least 2 years</time_frame>
    <description>• This study will evaluate the impacts of nilotinib combined with chemotherapy on duration of CR, relapse-free survival (RFS), event-free survival (EFS), and overall survival (OS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Chronic Myeloid Leukemia in Myeloid Blast Crisis</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Nilotinib+AD induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nilotinib plus AD induction chemotherapy
AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)
Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib+AD induction</intervention_name>
    <description>• Post-remission consolidation chemotherapy
4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).
Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation</description>
    <arm_group_label>Nilotinib+AD induction</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with previously-untreated patients having bcr-abl gene rearrangement (or
             t(9;22)) and 20% or more of myeloid blasts in bone marrow and/or blood, or converted
             CML CP/AP to MBP after initial imatinib treatment.

          -  15 years old or older, but 65 years or younger

          -  Adequate performance status (Karnofsky score of 50 or more)

          -  Adequate hepatic and renal function (AST, ALT, bilirubin and creatinine &lt; 2.5 x upper
             normal limit). Elevation of AST or ALT due to hepatic infiltration of leukemic cells
             will be permitted.

          -  Adequate cardiac function (left ventricular ejection fraction of 45% or more on heart
             scan or echocardiogram)

          -  Signed and dated informed consent must be obtained.

        Exclusion Criteria:

          -  Patients without bcr-abl gene rearrangement

          -  Acute lymphoblastic leukemia with bcr-abl gene rearrangement or t(9;22)

          -  Any previous history of TKIs except for imatinib in CML CP.

          -  Therapy-related leukemia or leukemia after myelodysplastic syndrome.

          -  Patients with CNS leukemia

          -  Patients with primary granulocytic sarcoma without bone marrow involvement

          -  Prior chemotherapy for leukemia or anthracycline treatment for any malignancy.
             Hydroxyurea for reduction of leukemic cell burden before induction chemotherapy will
             be permitted.

          -  Presence of significant active infection

          -  Presence of uncontrolled bleeding

          -  Significant cardiovascular disease including myocardial infarction within previous 6
             months

          -  Cardiac dysfunction: LVEF &lt; 45% or institutional lower normal range (any higher value
             of them) by echocardiogram or MUGA scan; Long QT syndrome or its family history;
             Clinically significant resting bradycardia (&lt;50 beats/minute); QTc &gt; 450 msec (by QTcF
             formula) on baseline ECG . If QTcF &gt; 450 msec and electrolytes are abnormal, retest
             QTc after the correction of electrolytes; Myocardial infarction within 12 months;
             Other clinically significant cardiac diseases (for example, unstable angina,
             congestive heart failure, uncontrolled hypertension or uncontrolled arrhythmia)

          -  Chronic or acute hepatic disease, pancreatic disease or severe renal disease

          -  Severe or life-threatening other medical conditions

          -  Any coexisting major illness or organ failure

          -  Patients with psychiatric disorder or mental deficiency severe as to make compliance
             with the treatment unlike, and making informed consent impossible History of
             congenital or acquired coagulopathy unrelated to malignancy

          -  Pregnancy issues: (a) pregnant woman, (b) lactating woman, (c) reproductive woman who
             does not confirm negative baseline pregnancy test (d) man or reproductive woman who
             cannot continue an appropriate contraceptive method (postmenopausal woman who has no
             menstruation for last 12 months is considered as non-reproductive)

          -  Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years
             following therapy with curative intent (except curatively treated nonmelanoma skin
             cancer, in situ carcinoma, or cervical intraepithelial neoplasia)

          -  History of non-compliance or patient who cannot sign informed consent

          -  Hypersensitivity to nilotinib or any of the experience

          -  Concurrent medications (Gastrointestinal dysfunction that can significantly change the
             absorption of test drug; - Strong CYP3A4 inhibitor and cannot stop or change the
             medication before starting study; Medication to prolong QT interval and cannot stop or
             change the medication before starting study) • The capsules contain lactose, and
             nilotinib is therefore not recommended for patients with rare hereditary problems of
             galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hawk Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hawk Kim, M.D., Ph.D.</last_name>
    <phone>+82-52-250-8892</phone>
    <email>kimhawkmd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Jung Kim, R.N.</last_name>
    <phone>+82-52-250-8515</phone>
    <email>enael@nate.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Wook Kim, M.D., Ph.D.</last_name>
      <email>dwkim@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Wook Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hawk Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae-Hoo Park, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae-Cheol Jo, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004.</citation>
    <PMID>12637609</PMID>
  </reference>
  <reference>
    <citation>Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun;23(6):1054-61. doi: 10.1038/leu.2009.38. Epub 2009 Mar 12. Erratum in: Leukemia. 2010 May;24(5):1102.</citation>
    <PMID>19282833</PMID>
  </reference>
  <reference>
    <citation>Bauduer F, Delmer A, Blanc MC, Delmas-Marsalet B, Cadiou M, Rio B, Marie JP, Zittoun R. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma. 1993 Jun;10(3):195-200. Review.</citation>
    <PMID>8220118</PMID>
  </reference>
  <reference>
    <citation>Coleman M, Silver RT, Pajak TF, Cavalli F, Rai KR, Kostinas JE, Glidewell O, Holland JF. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood. 1980 Jan;55(1):29-36.</citation>
    <PMID>6927956</PMID>
  </reference>
  <reference>
    <citation>Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia. 1992 Aug;6(8):770-5.</citation>
    <PMID>1379312</PMID>
  </reference>
  <reference>
    <citation>Dutcher JP, Lee S, Paietta E, Bennett JM, Stewart JA, Wiernik PH. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia. 1998 Jul;12(7):1037-40.</citation>
    <PMID>9665187</PMID>
  </reference>
  <reference>
    <citation>Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol. 1993 Oct;11(10):2002-9.</citation>
    <PMID>8410125</PMID>
  </reference>
  <reference>
    <citation>Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec;27(12):1091-6.</citation>
    <PMID>12921945</PMID>
  </reference>
  <reference>
    <citation>Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 1;98(3):522-8.</citation>
    <PMID>12879469</PMID>
  </reference>
  <reference>
    <citation>Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986 Dec 4;315(23):1433-8.</citation>
    <PMID>2431313</PMID>
  </reference>
  <reference>
    <citation>O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995 Nov 1;86(9):3322-6.</citation>
    <PMID>7579434</PMID>
  </reference>
  <reference>
    <citation>Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15;107(2):480-2. Epub 2005 Sep 29.</citation>
    <PMID>16195326</PMID>
  </reference>
  <reference>
    <citation>Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002 May 15;99(10):3547-53.</citation>
    <PMID>11986206</PMID>
  </reference>
  <reference>
    <citation>Morimoto A, Ogami A, Chiyonobu T, Takanashi M, Sugimoto T, Imamura T, Ishida H, Yoshihara T, Imashuku S. Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate. J Pediatr Hematol Oncol. 2004 May;26(5):320-2.</citation>
    <PMID>15111787</PMID>
  </reference>
  <reference>
    <citation>Pavlu J, Czepulkowski B, Kaczmarski R, Jan-Mohamed R. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. Lancet Oncol. 2005 Feb;6(2):128.</citation>
    <PMID>15683824</PMID>
  </reference>
  <reference>
    <citation>Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica. 2003 Nov;88(11):1213-20.</citation>
    <PMID>14607749</PMID>
  </reference>
  <reference>
    <citation>Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14.</citation>
    <PMID>19144656</PMID>
  </reference>
  <reference>
    <citation>Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.</citation>
    <PMID>20525993</PMID>
  </reference>
  <reference>
    <citation>Doggrell SA, Christensen AM. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. Expert Opin Pharmacother. 2011 Jan;12(1):157-63. doi: 10.1517/14656566.2011.534780. Epub 2010 Nov 26.</citation>
    <PMID>21108601</PMID>
  </reference>
  <reference>
    <citation>Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20;28(3):392-7. doi: 10.1200/JCO.2009.25.4896. Epub 2009 Dec 14.</citation>
    <PMID>20008621</PMID>
  </reference>
  <reference>
    <citation>Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12.</citation>
    <PMID>19822896</PMID>
  </reference>
  <reference>
    <citation>Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21;113(21):5058-63. doi: 10.1182/blood-2008-10-184960. Epub 2009 Mar 12.</citation>
    <PMID>19282457</PMID>
  </reference>
  <reference>
    <citation>Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 2010 Jun 15;4:207-13.</citation>
    <PMID>20694077</PMID>
  </reference>
  <reference>
    <citation>Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, Kim WK, Lee JS, Seo EJ, Jang S, Park CJ, Chi HS. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005 Sep;19(9):1509-16.</citation>
    <PMID>16034462</PMID>
  </reference>
  <reference>
    <citation>Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, Lee JW, Min WS, Kim CC. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2005 May 1;105(9):3449-57. Epub 2005 Jan 18.</citation>
    <PMID>15657178</PMID>
  </reference>
  <reference>
    <citation>Potenza L, Luppi M, Riva G, Marasca R, Martinelli S, Torelli G. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. Haematologica. 2005 Sep;90(9):1275-7.</citation>
    <PMID>16154854</PMID>
  </reference>
  <reference>
    <citation>Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chronique; Group for Research in Adult Acute Lymphoblastic Leukemia. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006 Mar;20(3):400-3.</citation>
    <PMID>16437142</PMID>
  </reference>
  <reference>
    <citation>Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15;103(12):4396-407. Epub 2003 Oct 9.</citation>
    <PMID>14551133</PMID>
  </reference>
  <reference>
    <citation>Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006 Sep 1;108(5):1469-77. Epub 2006 Apr 25.</citation>
    <PMID>16638934</PMID>
  </reference>
  <reference>
    <citation>Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.</citation>
    <PMID>19776406</PMID>
  </reference>
  <reference>
    <citation>Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409. Erratum in: N Engl J Med. 2010 Mar 25;362(12):1155. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.</citation>
    <PMID>19776405</PMID>
  </reference>
  <reference>
    <citation>Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005 Jul 15;106(2):458-63. Epub 2005 Apr 7.</citation>
    <PMID>15817679</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ulsan University Hospital</investigator_affiliation>
    <investigator_full_name>Hawk Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>myeloid blastic phase</keyword>
  <keyword>bcr-abl(+) acute myeloid leukemia</keyword>
  <keyword>nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

